Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Optimal management of adults with severe aortic stenosis (AS) remains controversial with several ongoing clinical trials evaluating the potential benefit of aortic valve replacement (AVR) earlier in the disease course when patients are still asymptomatic. To a large extent, these trials are based on evidence from the Contemporary Outcomes after Surgery and Medical Treatment in Patients with Severe Aortic Stenosis (CURRENT AS) registry.1 A comprehensive review article by the CURRENT-AS investigators in this issue of Heart summarises the data from this large Japanese multi-centre retrospective registry of consecutive adults with severe AS (figure 1). Both clinicians caring for patients with AS and researchers engaged in (or thinking about) clinical trials will want to read this data summary and review.
As we learn more about the disease course in adults with AS, the complex interaction between progressive valve obstruction and concurrent ventricular and vascular changes is increasingly evident. In a study of 1383 patients with severe AS undergoing AVR, Thaden and colleagues2 found that Doppler evidence of an elevated left ventricular (LV) filling pressure was present in 43% before AVR and was an independent predictor of increased mortality after AVR, even with adjustment for age, sex and other factors (HR 1.45, 95% CI 1.16 to 1.81, p=0.005) (figure 2).
Dr Flynn’s accompanying editorial3 points out that elevated LV filling pressures in patients with severe AS are most likely related to myocardial fibrosis, which may or may not reverse after AVR. He concludes: ‘The present study identifies a useful variable that will help inform our decision-making, but perhaps the greater impact of the study is that it highlights the ongoing need for increased understanding of the enthralling complexity that is aortic stenosis.’
Cardiac imaging now is a standard approach for monitoring cardiac function in patients receiving cancer therapies associated with LV dysfunction. However, measurement variability can lead to uncertainty in clinical decision making. In this issue of Heart, Lambert and colleagues4 report a carefully done study of temporal changes in several imaging measure of LV systolic function in 30 women receiving anthracyclines and trastuzumab for breast cancer compared with 30 control subjects. There was considerable temporal variability in all measure of LV function in both patients and control subjects. Interobsever and intraobserver variability were lowest for 2D-echocardiographic global longitudinal strain (2D-GLS) and cardiac magnetic resonance LV ejection fraction (CMR-LVEF) (figure 3).
In an editorial, Palaskas and Lopex-Mattei5 discuss the typical definition of cancer-therapeutic-related cardiac dysfunction (CRTCD)—a decline in LV ejection fraction by 10% to a value below 53%–55% in asymptomatic patients. The goal of periodic imaging is to detect early dysfunction and modify cancer therapy accordingly. However, ‘This brings up the important issue of reproducibility and reliability with any imaging modality and especially with cardiovascular imaging in patients with cancer where small changes can lead to life-changing treatment decisions. When a decline in LVEF is observed, we must be able to distinguish between a true change in a patient’s cardiac function vs an expected variability of an imperfect test’ (figure 4).
In a study addressing the impact of comorbidities on outcomes in adults with ischaemic heart disease, Crowe and colleagues6 use latent class analysis to identified five distinct comorbidity clusters. Interesting the two groups of patients at highest risk were those with vascular and musculoskeletal conditions (HR 2.38, 95% CI 2.28 to 2.49) and those with respiratory and musculoskeletal conditions (HR 2.62, 95% CI 2.45 to 2.79). In the linked editorial, Bridgman7 concludes that ‘The hitherto hidden mortality impact of a musculoskeletal condition when associated with either further cardiovascular disease or respiratory disease that has emerged in this study is significant. Cardiologists should be alert to these combinations in their patients and factor the increased mortality risk into their decision-making. Meeting the comorbid patient should not be a heart sink moment.’
The Education in Heart article in this issue compares the effects of lifestyle changes and pharmacological treatment on cardiovascular disease risk factors.8 As the author notes: ‘Adequately implemented, changes in lifestyle achieve reductions in cardiovascular risk factors close to those of single drug therapies and should be systematically proposed to all subjects with cardiovascular risk factors.’
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.